Masimo Corporation (MASI)

NASDAQ: MASI · IEX Real-Time Price · USD
-0.06 (-0.04%)
Sep 27, 2022 4:00 PM EDT - Market closed
Market Cap 7.35B
Revenue (ttm) 1.50B
Net Income (ttm) 190.72M
Shares Out 52.53M
EPS (ttm) 3.33
PE Ratio 42.05
Forward PE 40.00
Dividend n/a
Ex-Dividend Date n/a
Volume 322,930
Open 142.60
Previous Close 140.07
Day's Range 138.30 - 142.97
52-Week Range 112.07 - 305.21
Beta 0.96
Analysts Buy
Price Target 174.83 (+24.9%)
Earnings Date Oct 24, 2022

About MASI

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion ind... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Aug 8, 2007
CEO Joseph Kiani
Employees 2,200
Stock Exchange NASDAQ
Ticker Symbol MASI
Full Company Profile

Financial Performance

In 2021, Masimo's revenue was $1.24 billion, an increase of 8.34% compared to the previous year's $1.14 billion. Earnings were $229.65 million, a decrease of -4.43%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MASI stock is "Buy." The 12-month stock price forecast is 174.83, which is an increase of 24.87% from the latest price.

Price Target
(24.87% upside)
Analyst Consensus: Buy
Stock Forecasts


Masimo Appoints New Leader for Consumer Division

IRVINE, Calif.--(BUSINESS WIRE)--Masimo has named Blair Tripodi Chief Operating Officer of its Consumer division.

1 week ago - Business Wire

Masimo's (MASI) Latest Watch to Improve Patient Outcomes

Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.

3 weeks ago - Zacks Investment Research

Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1™, the First Watch to Offer Accurat...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo W1™, the first watch to offer accurate, continuous health data from the leader in hospital pulse oximetry, is now available for purchase.

3 weeks ago - Business Wire

Keltic Canada Development Celebrates Groundbreaking to Kick Off Construction of New Masimo Vancouver Facility

VANCOUVER, British Columbia--(BUSINESS WIRE)--Keltic Canada Development (Keltic) is proud to announce it will be breaking ground on its newest health-innovation project. Building off recent and successf...

4 weeks ago - Business Wire

How activist Politan Capital may find an opportunity to trim costs, build value at Masimo

Politan Capital has an 8.4% stake in pulse oximetry company Masimo. There may be an opportunity to help the company trim costs.

1 month ago - CNBC

New York Times, Masimo See Activist Action

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Other symbols: NYT
1 month ago - Market Watch

Activist Politan Capital Has 9% Stake in Masimo

The medical-device company's shares plummeted earlier this year when it entered into an ill-received acquisition deal.

1 month ago - WSJ

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.

1 month ago - Zacks Investment Research

Masimo (MASI) Q2 Earnings and Revenues Top Estimates

Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Masimo Reports Second Quarter 2022 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the second quarter of 2022, ended July 2, 2022. Second Quarter 2022 Financial Results Consolidated revenu...

1 month ago - Business Wire

Masimo to Report Second Quarter 2022 Financial Results after Market Close on Tuesday, August 9

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release second quarter 2022 financial results for the period ended July 2, 2022, after the market closes on Tuesday, August 9, 2022. The confe...

2 months ago - Business Wire

Randomized Controlled Study Finds Masimo SedLine® Brain Function Monitoring Can Help Guide Anesthesia in Children Und...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that Masimo SedLine® brain function monitoring helped clinicians use less sevoflurane to maintain anesthesia in pediatric patients.

2 months ago - Business Wire

7 Best High-Growth Stocks for Young Investors

Growth stocks have historically outperformed the rest of the market, so when the economy recovers, growth stocks will lead the surge higher. The post 7 Best High-Growth Stocks for Young Investors appear...

2 months ago - InvestorPlace

Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome

Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.

2 months ago - Zacks Investment Research

Two-part Study Finds That Remote Patient Monitoring with Masimo SafetyNet® Reduced Length of Hospital Stay for COVID-...

IRVINE, Calif.--(BUSINESS WIRE)--A new study evaluated the impact of remote patient monitoring with Masimo SafetyNet® on hospital length of stay for COVID-19 patients.

2 months ago - Business Wire

3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

2 months ago - Zacks Investment Research

Why Is Masimo (MASI) Up 6.9% Since Last Earnings Report?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think " Yes "

Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 months ago - Zacks Investment Research

Here's Why You Must Add Masimo (MASI) Stock to Your Portfolio

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

4 months ago - Zacks Investment Research

Masimo's (MASI) PVi Favored by New Study for Pediatric Patients

Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs.

4 months ago - Zacks Investment Research

New Study Finds That Masimo PVi® May Be Useful in Helping ER Doctors Determine the Severity of Asthma Attacks in Pedi...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A study investigated the ability of Masimo PVi® to guide ER triage decisions for pediatric patients with obstructive respiratory disease.

4 months ago - Business Wire

Can Masimo (MASI) Run Higher on Rising Earnings Estimates?

Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

4 months ago - Zacks Investment Research

Masimo CEO talks acquisition of Sound United

CNBC's Jim Cramer spoke with Masimo CEO Joe Kiani on Monday's episode of "Mad Money."

4 months ago - CNBC Television

Wall Street Analysts Think Masimo (MASI) Could Surge 135%: Read This Before Placing a Bet

The mean of analysts' price targets for Masimo (MASI) points to a 134.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

4 months ago - Zacks Investment Research

Masimo Closes a Questionable Acquisition

Masimo ( MASI , Financial) is a relatively unknown mid-cap medical technology player which focuses on the development, manufacturing and marketing of non-invasive patient monitoring technologies. Founde...

4 months ago - GuruFocus